Enrique Grande: NECTIN4 amplifications appear in ~25% of metastatic cases
Enrique Grande, Associate Professor at Francisco de Vitoria University, shared on LinkedIn:
“New insights in urothelial carcinoma:
NECTIN4 amplifications appear in ~25% of metastatic cases and strongly predict response to enfortumab vedotin. In this study, 96% of patients with NECTIN4 amplification responded, versus 32% without.
These findings could guide future treatment strategies and improve patient outcomes.”
Authors: Niklas Klümper, Ngoc Khanh Tran, Stefanie Zschäbitz, Oliver Hahn, Thomas Büttner, Florian Roghmann, Christian Bolenz, Friedemann Zengerling, Constantin Schwab, Dora Nagy, Marieta Toma, Glen Kristiansen, Hendrik Heers, Philipp Ivanyi, Günter Niegisch, Camilla Marisa Grunewald, Christopher Darr, Arian Farid, Katrin Schlack, Mahmoud Abbas, Can Aydogdu, Jozefina Casuscelli, Theresa Mokry, Michael Mayr, Dora Niedersüß-Beke, Steffen Rausch, Dimo Dietrich, Jonas Saal, Jörg Ellinger, Manuel Ritter, Abdullah Alajati, Christoph Kuppe, Joshua Meeks, Francisco E. Vera Badillo, J. Alberto Nakauma-González, Joost Boormans, Kerstin Junker, Arndt Hartmann, Viktor Grünwald, Michael Hölzel, Markus Eckstein,
Enrique Grande, MD, PhD, MSc, is an Associate Professor at Francisco de Vitoria University. He is also an Adjunct Professor at the GU Medical Oncology Department and the Head of Oncology at MD Anderson Cancer Center. Grande specializes in researching genitourinary and endocrine tumors and actively collaborates in developing the Translational Research and Early Drug Development Unit. He founded the Spanish Group for Research on Orphan and Uncommon Tumors (GETHI) and serves on the Directory Board of the Spanish Task Force Group for NETs (GETNE). Dr. Grande edits several international journals and has participated in recent neuroendocrine tumor trials that led to the approval of new drugs in this field.
Niklas Klümper is a senior urology consultant specializing in genitourinary (GU) oncology and an advanced clinician-scientist at the University Medical Center Bonn (UKB), supported by the BMBF-funded ACCENT program. He leads a translational uro-oncology research group that bridges the Department of Urology and the Institute of Experimental Oncology. His research focuses on improving treatment response predictions for targeted therapies, developing personalized treatment strategies, and conducting clinical trials to enhance outcomes for patients with uro-oncological diseases
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023